PDF herunterladen
The Journal of Hip Surgery 2017; 01(01): 003-006
DOI: 10.1055/s-0036-1597964
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Aging and Cell Therapy for the Treatment of Osteonecrosis of the Femoral Head

Emmanuel Gibon
1   Department of Orthopaedic Surgery, Stanford University, Stanford, California, United States
,
Stuart B. Goodman
1   Department of Orthopaedic Surgery, Stanford University, Stanford, California, United States
2   Department of Bioengineering, Stanford University, Stanford, California, United States
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
31. März 2017 (online)

    Lizenzen und Reprints

Abstract

The addition of mesenchymal stem cells (MSCs) to core decompression for the treatment of early-stage osteonecrosis of the femoral head (ONFH) represents a joint preserving operation to potentially avoid hip arthroplasty. The idea to regenerate the proximal femoral bone stock by replenishing the necrotic segment with viable MSCs has shown great promise compared with core decompression alone. However, the fate of the MSCs and the potential effects of aging have posed some important challenges. Aging affects the number of MSCs available for harvesting and injection, as well as their potential for differentiation into the osteogenic lineage, which are two critical parameters for the success of “cell-based therapy” for ONFH. This review endeavors to provide information relevant to the use of MSCs in aging patients for the treatment of ONFH.

Keywords

osteonecrosis of the femoral head - mesenchymal stem cells - aging
 

  • References

  • 1 Choi H-R, Steinberg ME Y Cheng E. Osteonecrosis of the femoral head: diagnosis and classification systems. Curr Rev Musculoskelet Med 2015; 8 (3) 210-220
    CrossrefPubMedGoogle Scholar
  • 2 Hungerford DS, Jones LC. Asymptomatic osteonecrosis: should it be treated?. Clin Orthop Relat Res 2004; (429) 124-130
    PubMedGoogle Scholar
  • 3 Bradway JK, Morrey BF. The natural history of the silent hip in bilateral atraumatic osteonecrosis. J Arthroplasty 1993; 8 (4) 383-387
    CrossrefPubMedGoogle Scholar
  • 4 Mont MA, Hungerford DS. Non-traumatic avascular necrosis of the femoral head. J Bone Joint Surg Am 1995; 77 (3) 459-474
    PubMedGoogle Scholar
  • 5 Mont MA, Jones LC, Hungerford DS. Nontraumatic osteonecrosis of the femoral head: ten years later. J Bone Joint Surg Am 2006; 88 (5) 1117-1132
    PubMedGoogle Scholar
  • 6 Wang C, Wang Y, Meng H-Y , et al. Application of bone marrow mesenchymal stem cells to the treatment of osteonecrosis of the femoral head. Int J Clin Exp Med 2015; 8 (3) 3127-3135
    PubMedGoogle Scholar
  • 7 Amanatullah DF, Strauss EJ, Di Cesare PE. Current management options for osteonecrosis of the femoral head: part 1, diagnosis and nonoperative management. Am J Orthop 2011; 40 (9) E186-E192
    PubMedGoogle Scholar
  • 8 Wang J, Kalhor A, Lu S, Crawford R, Ni J-D, Xiao Y. iNOS expression and osteocyte apoptosis in idiopathic, non-traumatic osteonecrosis. Acta Orthop 2015; 86 (1) 134-141
    CrossrefPubMedGoogle Scholar
  • 9 Mutijima E, De Maertelaer V, Deprez M, Malaise M, Hauzeur J-P. The apoptosis of osteoblasts and osteocytes in femoral head osteonecrosis: its specificity and its distribution. Clin Rheumatol 2014; 33 (12) 1791-1795
    CrossrefPubMedGoogle Scholar
  • 10 Wang C, Wang X, Xu XL , et al. Bone microstructure and regional distribution of osteoblast and osteoclast activity in the osteonecrotic femoral head. PLoS One 2014; 9 (5) e96361
    CrossrefPubMedGoogle Scholar
  • 11 Powell C, Chang C, Gershwin ME. Current concepts on the pathogenesis and natural history of steroid-induced osteonecrosis. Clin Rev Allergy Immunol 2011; 41 (1) 102-113
    CrossrefPubMedGoogle Scholar
  • 12 Lavernia CJ, Sierra RJ, Grieco FR. Osteonecrosis of the femoral head. J Am Acad Orthop Surg 1999; 7 (4) 250-261
    PubMedGoogle Scholar
  • 13 Jaffe WL, Epstein M, Heyman N, Mankin HJ. The effect of cortisone on femoral and humeral heads in rabbits. An experimental study. Clin Orthop Relat Res 1972; 82 (82) 221-228
    PubMedGoogle Scholar
  • 14 Cui Q, Wang GJ, Su CC, Balian G. The Otto Aufranc Award. Lovastatin prevents steroid induced adipogenesis and osteonecrosis. Clin Orthop Relat Res 1997; (344) 8-19
    PubMedGoogle Scholar
  • 15 Jones Jr JP. Fat embolism and osteonecrosis. Orthop Clin North Am 1985; 16 (4) 595-633
    PubMedGoogle Scholar
  • 16 Wang GJ, Moga DB, Richemer WG, Sweet DE, Reger SI, Thompson RC. Cortisone induced bone changes and its response to lipid clearing agents. Clin Orthop Relat Res 1978; (130) 81-85
    PubMedGoogle Scholar
  • 17 Yamamoto T, Irisa T, Sugioka Y, Sueishi K. Effects of pulse methylprednisolone on bone and marrow tissues: corticosteroid-induced osteonecrosis in rabbits. Arthritis Rheum 1997; 40 (11) 2055-2064
    CrossrefPubMedGoogle Scholar
  • 18 Motomura G, Yamamoto T, Miyanishi K, Jingushi S, Iwamoto Y. Combined effects of an anticoagulant and a lipid-lowering agent on the prevention of steroid-induced osteonecrosis in rabbits. Arthritis Rheum 2004; 50 (10) 3387-3391
    CrossrefPubMedGoogle Scholar
  • 19 Motomura G, Yamamoto T, Miyanishi K, Kondo K, Hirota Y, Iwamoto Y. Risk factors for developing osteonecrosis after prophylaxis in steroid-treated rabbits. J Rheumatol 2008; 35 (12) 2391-2394
    CrossrefPubMedGoogle Scholar
  • 20 Motomura G, Yamamoto T, Irisa T, Miyanishi K, Nishida K, Iwamoto Y. Dose effects of corticosteroids on the development of osteonecrosis in rabbits. J Rheumatol 2008; 35 (12) 2395-2399
    CrossrefPubMedGoogle Scholar
  • 21 Hernigou P, Beaujean F. Treatment of osteonecrosis with autologous bone marrow grafting. Clin Orthop Relat Res 2002; (405) 14-23
    PubMedGoogle Scholar
  • 22 Hernigou P, Poignard A, Zilber S, Rouard H. Cell therapy of hip osteonecrosis with autologous bone marrow grafting. Indian J Orthop 2009; 43 (1) 40-45
    CrossrefPubMedGoogle Scholar
  • 23 Hernigou P, Homma Y, Flouzat Lachaniette CH , et al. Benefits of small volume and small syringe for bone marrow aspirations of mesenchymal stem cells. Int Orthop 2013; 37 (11) 2279-2287
    CrossrefPubMedGoogle Scholar
  • 24 Hernigou P, Flouzat-Lachaniette C-H, Delambre J , et al. Osteonecrosis repair with bone marrow cell therapies: state of the clinical art. Bone 2015; 70: 102-109
    CrossrefPubMedGoogle Scholar
  • 25 Hernigou P, Poignard A, Beaujean F, Rouard H. Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number and concentration of progenitor cells. J Bone Joint Surg Am 2005; 87 (7) 1430-1437
    CrossrefPubMedGoogle Scholar
  • 26 Goodman SB, Hwang KL. Treatment of secondary osteonecrosis of the knee with local debridement and osteoprogenitor cell grafting. J Arthroplasty 2015; 30 (11) 1892-1896
    CrossrefPubMedGoogle Scholar
  • 27 Prockop DJ. Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Mol Ther 2009; 17 (6) 939-946
    CrossrefPubMedGoogle Scholar
  • 28 Yan Z, Hang D, Guo C, Chen Z. Fate of mesenchymal stem cells transplanted to osteonecrosis of femoral head. J Orthop Res 2009; 27 (4) 442-446
    CrossrefPubMedGoogle Scholar
  • 29 Winer JP, Janmey PA, McCormick ME, Funaki M. Bone marrow-derived human mesenchymal stem cells become quiescent on soft substrates but remain responsive to chemical or mechanical stimuli. Tissue Eng Part A 2009; 15 (1) 147-154
    PubMedGoogle Scholar
  • 30 Satija NK, Singh VK, Verma YK , et al. Mesenchymal stem cell-based therapy: a new paradigm in regenerative medicine. J Cell Mol Med 2009; 13 (11–12): 4385-4402
    CrossrefPubMedGoogle Scholar
  • 31 Moosmann S, Hutter J, Moser C, Krombach F, Huss R. Milieu-adopted in vitro and in vivo differentiation of mesenchymal tissues derived from different adult human CD34-negative progenitor cell clones. Cells Tissues Organs 2005; 179 (3) 91-101
    CrossrefPubMedGoogle Scholar
  • 32 McLain RF, Fleming JE, Boehm CA, Muschler GF. Aspiration of osteoprogenitor cells for augmenting spinal fusion: comparison of progenitor cell concentrations from the vertebral body and iliac crest. J Bone Joint Surg Am 2005; 87 (12) 2655-2661
    CrossrefPubMedGoogle Scholar
  • 33 Muschler GF, Boehm C, Easley K. Aspiration to obtain osteoblast progenitor cells from human bone marrow: the influence of aspiration volume. J Bone Joint Surg Am 1997; 79 (11) 1699-1709
    CrossrefPubMedGoogle Scholar
  • 34 Castro-Malaspina H, Gay RE, Resnick G , et al. Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Blood 1980; 56 (2) 289-301
    PubMedGoogle Scholar
  • 35 Baxter MA, Wynn RF, Jowitt SN, Wraith JE, Fairbairn LJ, Bellantuono I. Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells 2004; 22 (5) 675-682
    CrossrefPubMedGoogle Scholar
  • 36 Zhou S, Greenberger JS, Epperly MW , et al. Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts. Aging Cell 2008; 7 (3) 335-343
    CrossrefPubMedGoogle Scholar
  • 37 Kuehn BM. Genetic flaws found in aging stem cell lines. JAMA 2005; 294 (15) 1883-1884
    CrossrefPubMedGoogle Scholar
  • 38 D'Ippolito G, Schiller PC, Ricordi C, Roos BA, Howard GA. Age-related osteogenic potential of mesenchymal stromal stem cells from human vertebral bone marrow. J Bone Miner Res 1999; 14 (7) 1115-1122
    CrossrefPubMedGoogle Scholar
  • 39 Liu L, DiGirolamo CM, Navarro PAAS, Blasco MA, Keefe DL. Telomerase deficiency impairs differentiation of mesenchymal stem cells. Exp Cell Res 2004; 294 (1) 1-8
    CrossrefPubMedGoogle Scholar
  • 40 Pignolo RJ, Suda RK, McMillan EA , et al. Defects in telomere maintenance molecules impair osteoblast differentiation and promote osteoporosis. Aging Cell 2008; 7 (1) 23-31
    CrossrefPubMedGoogle Scholar
  • 41 Shigeno Y, Ashton BA. Human bone-cell proliferation in vitro decreases with human donor age. J Bone Joint Surg Br 1995; 77 (1) 139-142
    PubMedGoogle Scholar
  • 42 Muschler GF, Nitto H, Boehm CA, Easley KA. Age- and gender-related changes in the cellularity of human bone marrow and the prevalence of osteoblastic progenitors. J Orthop Res 2001; 19 (1) 117-125
    CrossrefPubMedGoogle Scholar
  • 43 Stolzing A, Jones E, McGonagle D, Scutt A. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev 2008; 129 (3) 163-173
    CrossrefPubMedGoogle Scholar
  • 44 Quarto R, Thomas D, Liang CT. Bone progenitor cell deficits and the age-associated decline in bone repair capacity. Calcif Tissue Int 1995; 56 (2) 123-129
    CrossrefPubMedGoogle Scholar
  • 45 Chen TL. Inhibition of growth and differentiation of osteoprogenitors in mouse bone marrow stromal cell cultures by increased donor age and glucocorticoid treatment. Bone 2004; 35 (1) 83-95
    CrossrefPubMedGoogle Scholar